Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 195
interventional 156
Observational 33
Registry 6

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 91
Drug|placebo 30
Other 9
Device 8
Procedure 6
Behavioral 2
Dietary Supplement 2
Biological 1
Biological|placebo 1
Device|Drug|placebo 1
Diagnostic Test 1
Drug|Other 1
Other|Procedure 1
Other|Procedure|Radiation 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 55
NA 8
Canada 6
China 4
United Kingdom 4
France 3
Germany 3
Korea, Republic of 3
United States|Canada 3
Austria 2
Belgium|Canada|France|Italy|Netherlands|Spain 2
Japan 2
Spain 2
Turkey 2
United States|Argentina|Australia|Austria|Brazil|Canada|Chile|China|Denmark|France|Germany|Greece|India|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Singapore|Sweden|Taiwan|United Kingdom 2
United States|Australia|Austria|Belgium|Canada|France|Germany|Italy|Netherlands|Spain|United Kingdom 2
United States|Austria|Germany 2
United States|France|Germany|Italy|Netherlands|Switzerland|United Kingdom 2
United States|Israel 2
Argentina|Brazil|Chile|Mexico 1
Austria|Belgium|France|Germany|Hungary|Italy|Poland|United Kingdom 1
Austria|Germany 1
Brazil 1
Canada|United States|Argentina|Australia|Austria|Belarus|Belgium|Chile|China|Colombia|Czechia|Denmark|France|Germany|Greece|Hungary|India|Ireland|Israel|Korea, Republic of|Malaysia|Mexico|Netherlands|Peru|Poland|Romania|Russian Federation|Serbia|Singapore|Slovakia|Spain|Sweden|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
China|Germany|United Kingdom 1
France|Belarus|Ukraine 1
France|Germany 1
France|Italy|Spain 1
Greece 1
Moldova, Republic of 1
Sweden 1
Sweden|United States|Argentina|Australia|Austria|Belarus|Belgium|Canada|Chile|China|Colombia|Czechia|Denmark|France|Germany|Greece|Hungary|India|Ireland|Israel|Italy|Korea, Republic of|Malaysia|Mexico|Netherlands|Peru|Poland|Romania|Russian Federation|Serbia|Singapore|Slovakia|Spain|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belarus|Belgium|Brazil|Canada|China|Colombia|Czechia|Denmark|France|Germany|Hungary|Israel|Italy|Korea, Republic of|Malaysia|Mexico|Netherlands|Norway|Poland|Portugal|Romania|Russian Federation|Serbia|Singapore|Slovakia|Spain|Sweden|Taiwan|Thailand|Turkey|Ukraine|United Kingdom|Vietnam 1
United States|Argentina|Australia|Austria|Belarus|Belgium|Bulgaria|Canada|Chile|China|Colombia|Croatia|Finland|France|Germany|Hong Kong|Hungary|India|Israel|Italy|Malaysia|Mexico|Netherlands|Peru|Poland|Romania|Russian Federation|Serbia|Singapore|Slovakia|South Africa|Sweden|Taiwan|Thailand|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belarus|Belgium|Bulgaria|Canada|Chile|China|Colombia|Croatia|France|Germany|Hong Kong|Hungary|India|Israel|Italy|Malaysia|Mexico|Netherlands|Norway|Peru|Poland|Romania|Russian Federation|Serbia|Singapore|Slovakia|South Africa|Spain|Sweden|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|China|Croatia|Czechia|Denmark|France|Greece|Hungary|Israel|Italy|Korea, Republic of|Poland|Romania|Singapore|Spain|Sweden|Taiwan|Ukraine|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|China|Croatia|Czechia|Denmark|France|Greece|Hungary|Israel|Italy|Korea, Republic of|Poland|Romania|Singapore|Spain|Taiwan|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Denmark|France|Germany|Ireland|Italy|Netherlands|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|France|Germany|India|Ireland|Israel|Italy|Mexico|Netherlands|Poland|Portugal|Puerto Rico|Spain|Sweden|United Kingdom 1
United States|Australia|Austria|Canada|China|Colombia|Finland|France|Hungary|Israel|Korea, Republic of|Malaysia|Mexico|Philippines|Poland|Portugal|Russian Federation|South Africa|Spain|Thailand|Ukraine|Vietnam 1
United States|Australia|Belarus|China|Czechia|France|Germany|Hungary|India|Israel|Italy|Mexico|Netherlands|Poland|Russian Federation|Serbia|South Africa|Spain|Ukraine 1
United States|Australia|Belarus|China|Czechia|France|Germany|Hungary|India|Israel|Italy|Mexico|Poland|Russian Federation|Serbia|South Africa|Spain|Ukraine 1
United States|Australia|Belgium|Bosnia and Herzegovina|Croatia|Czechia|Germany|Greece|Hong Kong|Israel|Latvia|Malaysia|Mexico|Poland|Romania|Russian Federation|Serbia|Singapore|South Africa|Spain|Thailand|Turkey|Ukraine 1
United States|Australia|Belgium|Germany|Italy|Lithuania|United Kingdom 1
United States|Australia|Brazil|Bulgaria|Canada|Czechia|Germany|Hungary|Italy|Japan|Malaysia|Mexico|Poland|Russian Federation|South Africa|Spain|Taiwan|Turkey 1
United States|Australia|Brazil|France|Germany|Israel|Spain|United Kingdom 1
United States|Australia|Bulgaria|Czechia|Hungary|Poland|Romania|Serbia|Slovakia|Spain 1
United States|Australia|Bulgaria|Czechia|Hungary|Poland|Romania|Serbia|Spain 1
United States|Australia|Czech Republic|France|Germany|Greece|Israel|Italy|Taiwan|United Kingdom 1
United States|Australia|France|Germany|Hong Kong|Israel|Italy|Malaysia|Netherlands|Russian Federation|Singapore|United Kingdom 1
United States|Austria|Belgium|Brazil|Canada|Czechia|Denmark|France|Germany|Greece|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Spain|Taiwan|Turkey|United Kingdom 1
United States|Austria|Belgium|Canada|France|Germany|Italy|Japan|Korea, Republic of|Netherlands|Spain|Sweden|Switzerland|United Kingdom 1
United States|Austria|France|Germany|Ireland|Norway|Portugal|Sweden|Switzerland|United Kingdom 1
United States|Austria|Germany|United Kingdom 1
United States|Belarus|Canada|China|France|Germany|Hungary|Israel|Malaysia|Poland|Russian Federation|Serbia|Taiwan|Ukraine|United Kingdom 1
United States|Belgium|Czech Republic|Germany|Ireland|Romania 1
United States|Belgium|Czechia|Germany|Ireland|Romania 1
United States|Belgium|Ireland 1
United States|Brazil|Canada|Chile|Colombia|Guatemala|Hungary|India|Italy|Japan|Malaysia|Mexico|Peru|Poland|Russian Federation|Sweden|Taiwan 1
United States|Brazil|Chile|Colombia|Guatemala|Hungary|India|Italy|Japan|Malaysia|Mexico|Poland|Russian Federation|Sweden|Taiwan 1
United States|Brazil|Czech Republic|Denmark|Germany|Greece|Portugal|Saudi Arabia|Slovakia|Spain|Sweden|United Kingdom 1
United States|Canada|France|Germany|Italy|Netherlands|Spain|United Kingdom 1
United States|Canada|France|Poland|Spain|United Kingdom 1
United States|France|Netherlands|Spain|United Kingdom 1
United States|Germany 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 62
2 7
3 3
4 3
5 2
6 4
7 5
8 5
9 1
10 4
11 4
13 1
14 1
15 2
16 2
17 5
18 1
22 1
23 1
24 1
25 1
26 1
30 2
31 1
32 1
34 2
35 1
36 1
38 1
39 2
41 2
44 1
45 1
46 2
47 1
48 1
51 1
58 1
68 1
75 1
80 1
81 2
90 1
95 1
113 1
126 1
130 1
148 1
152 1
153 1
155 1
157 1
158 1
182 1
211 1

Phase

Phase Study_Count
Phase 3 43
Phase 2 37
N/A 31
Phase 4 21
Phase 1 14
Phase 1/Phase 2 6
Early Phase 1 2
Phase 2/Phase 3 2

Number of Arms

Number_of_Arms Count_of_Studies
1 74
2 49
3 14
4 8
NA 11

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 6 10.0 3.00000 10.00 3.00000 59 11.0000 2.00
1st Qu. 7 20.0 12.00000 12.50 18.00000 59 51.2500 30.00
Median 8 37.5 15.00000 20.00 32.00000 59 178.0000 39.00
Mean 8 66.0 19.57143 19.50 40.59459 59 295.0714 90.65
3rd Qu. 9 63.0 25.75000 25.25 60.00000 59 362.2500 101.25
Max. 10 629.0 45.00000 30.00 151.00000 59 1187.0000 429.00

Trial Group Type

group_type Group_Count
Experimental 170
Placebo Comparator 29
Active Comparator 25
Other 13
NA 11
No Intervention 6
Sham Comparator 3

Intervention Model

intervention_model Study_Count
Single Group Assignment 78
Parallel Assignment 61
Crossover Assignment 10
Sequential Assignment 4
NA 2
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 135
Diagnostic 7
Other 4
Basic Science 3
Screening 2
Supportive Care 2
NA 2
Health Services Research 1

Observational Studies

Studies by Country

Country Study_Count
United States 11
China 4
France 3
NA 3
Germany 2
Argentina 1
Belgium 1
Canada 1
France|Germany|Italy|Portugal|Spain|United Kingdom 1
Germany|Ireland 1
Italy 1
Korea, Republic of 1
Netherlands 1
Poland 1
United Kingdom 1

Sites per Study

Site_count Study_Count
1 26
2 2
3 1
6 1
10 1
43 1
88 1

Enrollment Metrics

Measure Observational
Min 5.0000
1st Qu 43.0000
Median 90.0000
Mean 365.4242
3rd Qu 150.0000
Max 3079.0000

Observation Model

observational_model Study_Count
Cohort 23
Case-Control 3
Case-Only 3
Other 3
NA 1

Time Perspective

time_perspective Study_Count
Prospective 23
Retrospective 5
Cross-Sectional 3
NA 2

Registries

Studies by Country

Country Study_Count
Netherlands 2
China 1
Korea, Republic of 1
NA 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 5
76 1

Enrollment Metrics

Measure Registries
Min 17.0000
1st Qu 122.7500
Median 440.0000
Mean 371.8333
3rd Qu 500.0000
Max 797.0000

Registry Model

observational_model Study_Count
Cohort 3
Case-Control 2
Case-Only 1

Time Perspective

time_perspective Study_Count
Prospective 4
Cross-Sectional 2

Follow-up

target_duration Study_Count
3 Years 2
2 Years 1
4 Years 1
5 Years 1
6 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03365479 Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03365479 Completed University of Giessen 2018-08-01
NCT04273945 Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT04273945 Recruiting Actelion 2023-10-31
NCT03904693 Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT03904693 Recruiting Actelion 2023-12-15
NCT03492177 A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03492177 Recruiting Actelion 2026-02-11
NCT03399604 Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil https://ClinicalTrials.gov/show/NCT03399604 Active, not recruiting Liquidia Technologies, Inc. 2019-05-06
NCT03315507 A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH https://ClinicalTrials.gov/show/NCT03315507 Completed PhaseBio Pharmaceuticals Inc. 2019-08-08
NCT03288025 Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) https://ClinicalTrials.gov/show/NCT03288025 Recruiting The Cleveland Clinic 2022-12-28
NCT03251872 Olaparib for PAH: a Pilot Study https://ClinicalTrials.gov/show/NCT03251872 Recruiting Laval University 2019-12-31
NCT03205085 Determinants of Right Heart Remodeling in Patients With CTEPH or PAH https://ClinicalTrials.gov/show/NCT03205085 Recruiting Centre Chirurgical Marie Lannelongue 2020-07-01
NCT03187678 Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03187678 Completed Actelion 2018-05-29
NCT03166306 Angiogenic Imaging in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03166306 Recruiting Brigham and Women’s Hospital 2019-10-31
NCT03145298 ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy https://ClinicalTrials.gov/show/NCT03145298 Recruiting Cedars-Sinai Medical Center 2020-01-01
NCT03105934 Repeatability of OCT and IV-US in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03105934 Completed Hospital Universitari Vall d’Hebron Research Institute 2017-10-18
NCT03078907 Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension. https://ClinicalTrials.gov/show/NCT03078907 Completed Actelion 2020-02-10
NCT03069716 A Mobile Health Intervention in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03069716 Active, not recruiting Vanderbilt University Medical Center 2020-06-30
NCT03057028 Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03057028 Completed Virginia Commonwealth University 2018-06-07
NCT03055221 TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT03055221 Completed United Therapeutics 2014-02-25
NCT02932410 A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT02932410 Recruiting Actelion 2022-07-14
NCT02911844 Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02911844 Completed University of Pennsylvania 2018-12-05
NCT02891850 Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy https://ClinicalTrials.gov/show/NCT02891850 Completed Bayer 2020-01-29
NCT02859194 The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients https://ClinicalTrials.gov/show/NCT02859194 Completed Yonsei University 2016-10-14
NCT02847260 Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) https://ClinicalTrials.gov/show/NCT02847260 Completed United Therapeutics 2014-03-31
NCT02790450 Acute Effects of Benzbromaron on the Pulmonary Circulation https://ClinicalTrials.gov/show/NCT02790450 Completed Medical University of Graz 2016-08-31
NCT02734953 Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH https://ClinicalTrials.gov/show/NCT02734953 Completed Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) 2016-08-31
NCT02676947 A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02676947 Completed Papworth Hospital NHS Foundation Trust 2018-02-18
NCT02664558 A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) https://ClinicalTrials.gov/show/NCT02664558 Completed Eiger BioPharmaceuticals 2017-11-30
NCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients https://ClinicalTrials.gov/show/NCT03626688 Recruiting United Therapeutics 2021-12-31
NCT00098072 Endothelial Cell Dysfunction in Pulmonary Hypertension https://ClinicalTrials.gov/show/NCT00098072 Completed National Institutes of Health Clinical Center (CC) 2009-07-08
NCT02558231 The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02558231 Active, not recruiting Actelion 2019-08-29
NCT02551653 Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients https://ClinicalTrials.gov/show/NCT02551653 Completed GlaxoSmithKline 2017-03-14
NCT02471183 Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02471183 Completed Actelion 2016-12-05
NCT02371733 Aerobic Exercise Training in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02371733 Completed Gazi University 2018-01-31
NCT02310672 REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension https://ClinicalTrials.gov/show/NCT02310672 Completed Actelion 2019-09-10
NCT02304198 Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH https://ClinicalTrials.gov/show/NCT02304198 Completed Dong-A ST Co., Ltd. 2016-02-29
NCT02279745 Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02279745 Active, not recruiting United Therapeutics 2020-08-31
NCT02279160 Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02279160 Completed Arena Pharmaceuticals 2017-06-30
NCT02234141 Selonsertib in Adults With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02234141 Completed Gilead Sciences 2016-04-30
NCT02223481 Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension https://ClinicalTrials.gov/show/NCT02223481 Completed Boehringer Ingelheim 1999-09-30
NCT02112487 Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH https://ClinicalTrials.gov/show/NCT02112487 Completed Actelion 2018-09-19
NCT02080533 Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02080533 Completed University of Pennsylvania 2015-03-31
NCT02060487 Effects of Oral Sildenafil on Mortality in Adults With PAH https://ClinicalTrials.gov/show/NCT02060487 Recruiting Pfizer 2023-06-30
NCT02032836 Comparative PK PD Study in PAH Patients (Fox vs. I-Neb) https://ClinicalTrials.gov/show/NCT02032836 Completed Bayer 2015-01-07
NCT02000856 BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02000856 Completed Uppsala University 2015-02-28
NCT01966302 Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT01966302 Completed Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center 2019-06-02
NCT01908699 Beraprost-314d Added-on to Tyvaso® (BEAT) https://ClinicalTrials.gov/show/NCT01908699 Completed Lung Biotechnology PBC 2019-02-19
NCT01841762 Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument https://ClinicalTrials.gov/show/NCT01841762 Completed Actelion 2015-11-01
NCT01757808 A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01757808 Completed University of Chicago 2015-01-31
NCT01712620 Spironolactone for Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01712620 Recruiting National Institutes of Health Clinical Center (CC) 2021-10-01
NCT01647945 FK506 (Tacrolimus) in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01647945 Completed Stanford University 2014-05-31
NCT01642407 Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01642407 Completed Pfizer 2016-05-20
NCT01613287 Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01613287 Completed Miltenyi Biotec B.V. & Co. KG 2013-08-31
NCT01590108 The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects https://ClinicalTrials.gov/show/NCT01590108 Completed Imperial College London 2014-09-30
NCT01588405 Remodulin® to Oral Treprostinil Transition https://ClinicalTrials.gov/show/NCT01588405 Completed United Therapeutics 2014-07-31
NCT01572077 Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01572077 Completed Ottawa Heart Institute Research Corporation 2016-12-31
NCT01560637 An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01560637 Active, not recruiting United Therapeutics 2021-05-31
NCT01560624 Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy https://ClinicalTrials.gov/show/NCT01560624 Completed United Therapeutics 2018-06-24
NCT01557582 Assessmet of Patients With PAH Right Ventricular Volume https://ClinicalTrials.gov/show/NCT01557582 Completed VentriPoint Diagnostics Ltd. 2013-11-30
NCT01553721 Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH) https://ClinicalTrials.gov/show/NCT01553721 Completed Dong-A ST Co., Ltd. 2015-03-31
NCT01548950 Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension https://ClinicalTrials.gov/show/NCT01548950 Completed University of Sao Paulo General Hospital 2014-01-31
NCT01545336 Anastrozole in Patients With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01545336 Completed University of Pennsylvania 2015-06-30
NCT01520493 Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01520493 Completed Laval University 2013-08-31
NCT01484431 A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01484431 Completed Eli Lilly and Company 2017-04-21
NCT01477333 Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso® https://ClinicalTrials.gov/show/NCT01477333 Completed United Therapeutics 2013-11-30
NCT01470144 Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01470144 Completed Actelion 2015-06-01
NCT01461343 Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging https://ClinicalTrials.gov/show/NCT01461343 Completed Massachusetts General Hospital 2017-11-21
NCT01457781 Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT01457781 Completed Bellerophon 2014-10-31
NCT01447628 IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients https://ClinicalTrials.gov/show/NCT01447628 Completed Imperial College London 2017-12-22
NCT01431716 Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01431716 Completed Actelion 2012-02-29
NCT01409122 Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects https://ClinicalTrials.gov/show/NCT01409122 Completed Aires Pharmaceuticals, Inc. 2012-01-31
NCT01397110 Respiratory and Physical Therapy in Patients With Associated Pulmonary Arterial Hypertension (APAH) With Congenital Heart Defects https://ClinicalTrials.gov/show/NCT01397110 Recruiting Heidelberg University 2025-12-31
NCT01392469 Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients https://ClinicalTrials.gov/show/NCT01392469 Completed Novartis 2012-10-25
NCT01391104 Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01391104 Completed Laval University 2011-11-30
NCT01338636 An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT01338636 Completed Brigham and Women’s Hospital 2016-02-29
NCT01338415 FUTURE 3 Study Extension https://ClinicalTrials.gov/show/NCT01338415 Active, not recruiting Actelion 2014-08-13
NCT01321073 DelIVery for Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT01321073 Active, not recruiting Medtronic Cardiac Rhythm and Heart Failure 2013-06-30
NCT03528902 Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03528902 Recruiting Vanderbilt University Medical Center 2022-06-30
NCT04316143 Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH https://ClinicalTrials.gov/show/NCT04316143 Recruiting Bial - Portela C S.A. 2020-08-31
NCT04125745 Oral CXA-10 in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT04125745 Active, not recruiting University of Pittsburgh 2023-06-30
NCT04062565 Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH https://ClinicalTrials.gov/show/NCT04062565 Recruiting University of Arizona 2020-12-31
NCT03992755 Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil https://ClinicalTrials.gov/show/NCT03992755 Active, not recruiting Liquidia Technologies, Inc. 2021-12-31
NCT03950739 Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso https://ClinicalTrials.gov/show/NCT03950739 Recruiting United Therapeutics 2020-05-31
NCT03926793 Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03926793 Recruiting Gossamer Bio Inc. 2020-06-30
NCT03905083 miRNA and Myokines in Patients With PAH https://ClinicalTrials.gov/show/NCT03905083 Recruiting University of Pittsburgh 2022-03-15
NCT03884465 Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil https://ClinicalTrials.gov/show/NCT03884465 Active, not recruiting Liquidia Technologies, Inc. 2020-11-30
NCT03841344 Repeatability and Sensitivity to Change of Non-invasive Endpoints in PAH https://ClinicalTrials.gov/show/NCT03841344 Active, not recruiting University of Sheffield 2018-09-24
NCT03795428 Long-Term, Open Label Extension Study of PB1046 in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 https://ClinicalTrials.gov/show/NCT03795428 Recruiting PhaseBio Pharmaceuticals Inc. 2024-01-15
NCT03782818 Olaparib for PAH: a Multicenter Clinical Trial https://ClinicalTrials.gov/show/NCT03782818 Recruiting Laval University 2021-11-12
NCT03744637 A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002) https://ClinicalTrials.gov/show/NCT03744637 Recruiting Merck Sharp & Dohme Corp. 2021-02-05
NCT03683082 Oxygen Treatment and Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03683082 Recruiting George Papanicolaou Hospital 2019-06-10
NCT03657095 BPS-314d-MR-PAH-303 (BEAT OLE) https://ClinicalTrials.gov/show/NCT03657095 Completed Lung Biotechnology PBC 2019-07-20
NCT03655704 Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study https://ClinicalTrials.gov/show/NCT03655704 Recruiting Laval University 2020-06-30
NCT03638908 Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial https://ClinicalTrials.gov/show/NCT03638908 Completed University of Texas Southwestern Medical Center 2017-05-31
NCT03554330 Combined Use of Radiofrequency-ablation and Balloon-septostomy in the Creation of a Stable Inter-atrial Communication https://ClinicalTrials.gov/show/NCT03554330 Recruiting China National Center for Cardiovascular Diseases 2020-12-30
NCT03497689 EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03497689 Recruiting United Therapeutics 2020-07-31
NCT03496207 A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT03496207 Active, not recruiting Acceleron Pharma, Inc. 2020-03-31
NCT03422328 A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Arterial Hypertension Who Were Previously Treated With Macitentan in Clinical Studies. https://ClinicalTrials.gov/show/NCT03422328 Enrolling by invitation Actelion 2021-04-03
NCT01265888 Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. https://ClinicalTrials.gov/show/NCT01265888 Completed Geno LLC 2016-09-30
NCT01223352 Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01223352 Completed Actelion 2013-04-03
NCT01208792 Auto-immunity and Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01208792 Completed Assistance Publique - Hôpitaux de Paris 2014-07-15
NCT01174173 Ranolazine and Pulmonary Hypertension https://ClinicalTrials.gov/show/NCT01174173 Completed Northwestern University 2014-01-31
NCT01148836 Coenzyme Q-10 and Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01148836 Completed The Cleveland Clinic 2014-01-31
NCT01112306 ACT-293987 in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01112306 Active, not recruiting Actelion 2020-12-31
NCT01106014 Selexipag (ACT-293987) in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01106014 Completed Actelion 2014-04-01
NCT01105117 Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401 https://ClinicalTrials.gov/show/NCT01105117 Completed Actelion 2011-07-31
NCT01105091 Epoprostenol for Injection in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01105091 Completed Actelion 2011-05-31
NCT01042158 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01042158 Completed Johns Hopkins University 2014-11-30
NCT01027949 An Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01027949 Active, not recruiting United Therapeutics 2020-12-31
NCT00993408 Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT00993408 Completed Actelion 2009-06-30
NCT00990314 Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients https://ClinicalTrials.gov/show/NCT00990314 Completed Lung Biotechnology PBC 2013-11-30
NCT00989963 Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT00989963 Completed Lung Biotechnology PBC 2011-12-31
NCT00964678 Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00964678 Completed Virginia Commonwealth University 2014-05-31
NCT00942708 Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00942708 Completed University of Texas Southwestern Medical Center 2011-06-30
NCT00902174 Imatinib (QTI571) in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00902174 Completed Novartis 2011-05-31
NCT01926509 Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005) https://ClinicalTrials.gov/show/NCT01926509 Completed Merck Sharp & Dohme Corp. 2014-09-01
NCT03612115 Neuromuscular Electrical Stimulation in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03612115 Completed Dokuz Eylul University 2017-09-28
NCT03282266 Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03282266 Recruiting Nanjing First Hospital, Nanjing Medical University 2021-07-30
NCT02961023 The Effect of Adding Exercise Training to Optimal Therapy in PAH https://ClinicalTrials.gov/show/NCT02961023 Completed National Health Service, United Kingdom 2018-07-31
NCT02579954 Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02579954 Recruiting Centre Hospitalier Universitaire de Saint Etienne 2020-12-31
NCT03683186 A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension https://ClinicalTrials.gov/show/NCT03683186 Enrolling by invitation United Therapeutics 2024-09-30
NCT03738150 A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT03738150 Recruiting Acceleron Pharma, Inc. 2021-12-31
NCT00792571 An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients https://ClinicalTrials.gov/show/NCT00792571 Completed Lung Biotechnology PBC 2013-11-30
NCT00741819 Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects https://ClinicalTrials.gov/show/NCT00741819 Completed United Therapeutics 2010-03-31
NCT00709956 Iloprost Power 15 in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00709956 Completed Actelion 2009-08-31
NCT00709098 Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00709098 Completed Actelion 2010-06-30
NCT00705133 Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00705133 Completed University of California, Los Angeles 2011-01-31
NCT00667823 Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00667823 Active, not recruiting Actelion 2020-06-30
NCT00660179 Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00660179 Completed Actelion 2012-03-31
NCT00641836 Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00641836 Completed Zhejiang University NA
NCT00626028 Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing https://ClinicalTrials.gov/show/NCT00626028 Completed Mallinckrodt 2010-02-28
NCT00617305 Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) https://ClinicalTrials.gov/show/NCT00617305 Completed Gilead Sciences 2011-02-28
NCT00609349 The Early Recognition of Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00609349 Completed Medical University of Graz 2009-05-31
NCT00578786 A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) https://ClinicalTrials.gov/show/NCT00578786 Completed Gilead Sciences 2010-03-31
NCT00566423 Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT00566423 Completed Northwell Health 2008-05-31
NCT00554619 A Study to Evaluate GSK1325760A - a Long-Term Extension Study https://ClinicalTrials.gov/show/NCT00554619 Completed GlaxoSmithKline 2011-01-31
NCT00477269 Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00477269 Completed Novartis 2014-01-31
NCT00452218 Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT00452218 Completed University of Chicago 2012-05-31
NCT00435331 6R-BH4 Pulmonary Arterial Hypertension Study https://ClinicalTrials.gov/show/NCT00435331 Completed Vanderbilt University 2008-09-30
NCT00433329 Combination Therapy in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00433329 Completed Actelion 2010-05-31
NCT00423748 Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. https://ClinicalTrials.gov/show/NCT00423748 Completed Gilead Sciences NA
NCT00423202 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. https://ClinicalTrials.gov/show/NCT00423202 Completed Gilead Sciences NA
NCT00367770 BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology https://ClinicalTrials.gov/show/NCT00367770 Completed Actelion 2005-12-31
NCT00323297 Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00323297 Completed Pfizer 2013-08-31
NCT00319267 Bosentan in Children With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00319267 Completed Actelion 2006-12-31
NCT00319020 Bosentan in Children With Pulmonary Arterial Hypertension Extension Study https://ClinicalTrials.gov/show/NCT00319020 Completed Actelion 2011-10-28
NCT00317486 Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology https://ClinicalTrials.gov/show/NCT00317486 Completed Actelion 2005-04-30
NCT00303459 Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT00303459 Completed Actelion 2013-12-31
NCT03556020 Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC PB1046 in Subjects With Symptomatic PAH https://ClinicalTrials.gov/show/NCT03556020 Recruiting PhaseBio Pharmaceuticals Inc. 2021-12-31
NCT00257413 Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00257413 Completed Zhejiang University NA
NCT00159913 A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension. https://ClinicalTrials.gov/show/NCT00159913 Completed Pfizer 2008-06-30
NCT00159874 A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children https://ClinicalTrials.gov/show/NCT00159874 Completed Pfizer 2012-12-31
NCT00105209 A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00105209 Completed Kawut, Steven, MD NA
NCT00086463 Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT00086463 Completed Actelion 2006-01-31
NCT00080457 Safety and Efficacy Study of Sitaxentan Sodium (Thelinâ„¢) in Patients With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00080457 Completed Encysive Pharmaceuticals NA
NCT00058929 A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00058929 Completed United Therapeutics 2005-08-31
NCT00004754 Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension https://ClinicalTrials.gov/show/NCT00004754 Completed Office of Rare Diseases (ORD) NA
NCT00004497 Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension https://ClinicalTrials.gov/show/NCT00004497 Completed FDA Office of Orphan Products Development NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03819777 Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT03819777 Recruiting Maastricht University Medical Center 2021-10-31
NCT02959723 Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies https://ClinicalTrials.gov/show/NCT02959723 Recruiting Universitaire Ziekenhuizen Leuven 2017-12-31
NCT02899533 [18F]FES PET/CT in PAH https://ClinicalTrials.gov/show/NCT02899533 Active, not recruiting University of Pennsylvania 2020-12-31
NCT02885155 Contribution of Echocardiography to Prognostic Evaluation of Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02885155 Completed Central Hospital, Nancy, France 2012-01-31
NCT02858791 MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02858791 Completed Northwell Health 2017-12-21
NCT02763735 Right Ventricular Metabolism in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02763735 Completed Vanderbilt University Medical Center 2019-06-30
NCT02565030 Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome https://ClinicalTrials.gov/show/NCT02565030 Active, not recruiting Sheffield Teaching Hospitals NHS Foundation Trust 2021-10-31
NCT02484807 Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH https://ClinicalTrials.gov/show/NCT02484807 Completed Heidelberg University 2016-12-31
NCT02318186 Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT02318186 Completed Stanford University 2017-08-01
NCT02260362 Observatory of Pulmonary Arterial Hypertension of Congenital Heart Disease https://ClinicalTrials.gov/show/NCT02260362 Active, not recruiting French Cardiology Society 2021-11-30
NCT02074449 Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin) https://ClinicalTrials.gov/show/NCT02074449 Completed University of Arizona 2015-12-31
NCT01884051 Hormonal, Metabolic, and Signaling Interactions in PAH https://ClinicalTrials.gov/show/NCT01884051 Recruiting Vanderbilt University Medical Center 2022-07-31
NCT01781052 Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients https://ClinicalTrials.gov/show/NCT01781052 Completed Bayer 2016-05-26
NCT01600898 Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers https://ClinicalTrials.gov/show/NCT01600898 Completed Assistance Publique - Hôpitaux de Paris 2016-07-31
NCT01451255 Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging https://ClinicalTrials.gov/show/NCT01451255 Completed Mayo Clinic 2014-06-30
NCT01445873 Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT01445873 Completed Pfizer 2011-03-31
NCT01417338 Registry for Pulmonary Hypertension in China https://ClinicalTrials.gov/show/NCT01417338 Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital 2019-12-31
NCT01365585 Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01365585 Completed Pfizer 2011-10-31
NCT01355380 Efficacy of Ventavis Used in Real-life Setting. https://ClinicalTrials.gov/show/NCT01355380 Completed Bayer 2016-04-28
NCT04282434 DNA Methylation Dynamics Underlying Arterial Remodeling in PAH Patients: CLEOPAHTRA Clinical Trial https://ClinicalTrials.gov/show/NCT04282434 Recruiting University of Campania “Luigi Vanvitelli” 2020-06-30
NCT04086537 BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT04086537 Recruiting Heidelberg University 2020-12-31
NCT04053296 Long-term Outcomes of Pregnant Women With PAH https://ClinicalTrials.gov/show/NCT04053296 Recruiting RenJi Hospital 2019-12-31
NCT03977428 Central China Congenital Heart Disease Associated Pulmonary Arterial Hypertension Cohort Study https://ClinicalTrials.gov/show/NCT03977428 Recruiting Wuhan Asia Heart Hospital 2022-12-30
NCT03889509 A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03889509 Active, not recruiting Lawson Health Research Institute 2020-03-01
NCT03888365 Patient Global Impression Questions for Activity-induced Symptoms in Patients With PAH https://ClinicalTrials.gov/show/NCT03888365 Completed United Therapeutics 2019-09-19
NCT03863990 Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the Lungs https://ClinicalTrials.gov/show/NCT03863990 Completed Bayer 2020-05-11
NCT01266265 Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies https://ClinicalTrials.gov/show/NCT01266265 Completed United Therapeutics 2014-12-31
NCT01181284 Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA) https://ClinicalTrials.gov/show/NCT01181284 Completed Mayo Clinic 2011-07-31
NCT01066845 Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01066845 Completed Eli Lilly and Company 2014-08-31
NCT01054105 Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01054105 Completed Gachon University Gil Medical Center 2018-12-25
NCT01043627 Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR) https://ClinicalTrials.gov/show/NCT01043627 Completed Mayo Clinic 2011-12-31
NCT00882947 Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH) https://ClinicalTrials.gov/show/NCT00882947 Completed Bayer 2008-09-30
NCT00250640 Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years https://ClinicalTrials.gov/show/NCT00250640 Completed Bayer 2012-04-30

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02391441 Ventricular Reversed Remodeling After LTX in PAH Patients https://ClinicalTrials.gov/show/NCT02391441 Completed University Medical Center Groningen 2019-08-31
NCT01389206 Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program https://ClinicalTrials.gov/show/NCT01389206 Completed Actelion 2018-04-10
NCT04130243 Biomarkers in Pediatric Congenital Heart Disease and PAH https://ClinicalTrials.gov/show/NCT04130243 Recruiting University Medical Center Groningen 2021-12-01
NCT03954405 Multi-marker Approach for Risk Assessment in PAH https://ClinicalTrials.gov/show/NCT03954405 Recruiting Wuhan Asia Heart Hospital 2019-12-30
NCT03933579 The PAH Platform for Deep Phenotyping in Korean Subjects https://ClinicalTrials.gov/show/NCT03933579 Recruiting Gachon University Gil Medical Center 2020-12-31
NCT03688698 PET/MRI in PAH Patients https://ClinicalTrials.gov/show/NCT03688698 Completed Medical University of Bialystok 2017-06-01